antibody

Parafibromin

MBS370317

5 Control Slides

130 USD

monoclonal

mouse

nonconjugated

human, mouse

immunohistochemistry, immunohistochemistry - paraffin section

Antibody

Parafibromin

[Parafibromin]

[parafibromin; Parafibromin; parafibromin; cell division cycle 73; Cell division cycle protein 73 homolog; Hyperparathyroidism 2 protein]

[CDC73; CDC73; HYX; FIHP; HPTJT; HRPT1; HRPT2; C1orf28; C1orf28; HRPT2]

CDC73_HUMAN

Monoclonal

IgG1

Mouse

Human, Mouse

531

Parafibromin is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Store at 2-8°C. Do not use after expiration date listed on package label. Temperature fluctuations should be avoided. Store appropriately when not in use, and avoid prolonged exposure to room temperature conditions.

Immunohistochemistry (IHC) Formalin/Paraffin

Dilution Information

Immunohistochemistry (IHC)

IHC Protocol

Localization: Nuclear. Control: Parathyroid, Colon, Testis, Adrenal, Breast, Cervix, Lymphoblastic Lymphoma, Bladder TCC. Precautions: 1. For professional users only. Ensure results are interpreted by a medical professional. 2. This product contains sodium azide (NaN3), a toxic chemical which may react with plumbing to form highly explosive build-ups of metal azides. Upon disposal, flush with large volumes of water to prevent sodium azide build-up. 3. Ensure proper handling procedures are used with reagent. Always wear proper laboratory equipment such as laboratory coat and gloves when handling reagents. 4. Unused solution should be disposed of according to local and federal regulations. 5. Do not ingest reagent. If reagent ingested, contact a poison control center immediately. 6. For complete recommendations for handling biological specimens please refer to the CDC document, “Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories” (4).

Intended Use: This antibody is intended for use in Immunohistochemical applications on formalinfixed paraffin-embedded tissues (FFPE), frozen tissue sections and cell preparations. Interpretation of results should be performed by a qualified medical professional. Immunogen: Synthetic peptide corresponding to the N-residues of human parafibromin. Specimen Preparation: Paraffin sections: The antibody can be used on formalin-fixed paraffin-embedded (FFPE) tissue sections. Ensure tissue undergoes appropriate fixation to ensure best results. Pre-treatment of tissues with heat-induced epitope retrieval (HIER) is recommended. Tissue should remain hydrated. Frozen sections and cell preparations: The antibody can be used for labeling acetone-fixed frozen sections and acetone-fixed cell preparations. Staining Procedure: 1. Cut and mount 3-5 micron formalin-fixed paraffin-embedded tissues on positive charged slides. 2. Air dry for 2 hours at 58° C. 3. Deparaffinize, dehydrate and rehydrate tissues. 4. Subject tissues to heat epitope retrieval using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate or EDTA. 5. Any of three heating methods may be used:. a. TintoRetriever Pressure Cooker or Equivalent Place tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA, and place in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room temperature. b. TintoRetriever PT Module or Water Bath Method Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes. c. Conventional Steamer Method Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a Steamer, cover and steam for 30-60 minutes. 6. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes. 7. For manual staining, perform antibody incubation at ambient temperature. For automated staining methods, perform antibody incubation according to instrument manufacturer’s instructions. 8. Wash slides with IHC wash buffer or DI water. 9. Continue IHC staining protocol.

Cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S.cerevisiae), also known as CDC73 and parafibromin, is a protein which in humans is encoded by the CDC73 gene. Mutations in the CDC73 gene are associated with hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid carcinomas.The proposed role of HRPT2 as a tumor suppressor was supported by mutation screening in parathyroid adenomas with cystic features, which identified three somatic inactivating mutations, all located in exon 1. None of these mutations were detected in normal controls, and all were predicted to cause deficient or impaired protein function. Sporadic parathyroid carcinomas frequently have HRPT2 mutations that are likely to be of pathogenetic importance. Certain patients with apparently sporadic parathyroid carcinoma carry germ-line mutations in HRPT2 and may have the HPT-JT syndrome or a phenotypic variant.

40018640

NP_078805.3

NM_024529.4

60,577 Da

Formation Of The Beta-catenin:TCF Transactivating Complex Pathway (1269602); Hedgehog 'on' State Pathway (1269640); Signal Transduction Pathway (1269379); Signaling By Hedgehog Pathway (1269633); Signaling By Wnt Pathway (1269594); TCF Dependent Signaling In Response To WNT Pathway (1269599)

This gene encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma. [provided by RefSeq, Jul 2009]

CDC73: Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non- phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both indepentently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of MLL1; it promotes leukemogenesis though association with MLL-rearranged oncoproteins, such as MLL-MLLT3/AF9 and MLL-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors. Component of the PAF1 complex, which consists of CDC73, PAF1, LEO1, CTR9, RTF1 and WDR61. Interacts with POLR2A, CPSF1, CPSF4, CSTF2, MLL and CTNNB1. Interacts with a Set1-like complex that has histone methyltransferase activity and methylates histone H3. Found in a complex with BCL9L or BCL9, CDC73, CTNNB1 and PYGO1 indicative for the participation in a nuclear Wnt signaling complex. Found in adrenal and parathyroid glands, kidney and heart. Belongs to the CDC73 family. Protein type: Tumor suppressor; Cell cycle regulation. Chromosomal Location of Human Ortholog: 1q25. Cellular Component: cytoplasm; nuclear chromosome, telomeric region; nucleoplasm; nucleus. Molecular Function: protein binding. Biological Process: cell cycle; endodermal cell fate commitment; histone H2B ubiquitination; histone monoubiquitination; mRNA polyadenylation; negative regulation of cell proliferation; negative regulation of epithelial cell proliferation; negative regulation of fibroblast proliferation; negative regulation of myeloid cell differentiation; negative regulation of transcription from RNA polymerase II promoter; positive regulation of mRNA 3'-end processing; positive regulation of RNA elongation from RNA polymerase II promoter; positive regulation of transcription from RNA polymerase II promoter; positive regulation of Wnt receptor signaling pathway; protein destabilization; RNA elongation from RNA polymerase II promoter; stem cell maintenance; Wnt receptor signaling pathway. Disease: Parathyroid Carcinoma

5 Control Slides

130 USD

3 ml (Prediluted)

170

0.1 mL (Concentrate)

190

7 mL (Prediluted)

265

0.5 mL (Concentrate)

480

15 mL (Prediluted)

480

1 mL (Concentrate)

800